Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 692 entries
Sorted by: Best Match Show Resources per page
Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report.

International journal of surgery case reports

Sato K, Tazawa H, Fujisaki S, Fukuhara S, Imaoka K, Hirata Y, Takahashi M, Fukuda S, Kuga Y, Nishida T, Sakimoto H.
PMID: 28888914
Int J Surg Case Rep. 2017;39:288-292. doi: 10.1016/j.ijscr.2017.08.041. Epub 2017 Aug 23.

INTRODUCTION: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Overt peritonitis caused by GIST rupture is very uncommon. Three types of GIST rupture have been described: closed perforation due to abscess (abscess type),...

Cite
Sato K, Tazawa H, Fujisaki S, et al. Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report. Int J Surg Case Rep. 2017;39:288-292doi: 10.1016/j.ijscr.2017.08.041.
Sato, K., Tazawa, H., Fujisaki, S., Fukuhara, S., Imaoka, K., Hirata, Y., Takahashi, M., Fukuda, S., Kuga, Y., Nishida, T., & Sakimoto, H. (2017). Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report. International journal of surgery case reports, 39288-292. https://doi.org/10.1016/j.ijscr.2017.08.041
Sato, Koki, et al. "Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report." International journal of surgery case reports vol. 39 (2017): 288-292. doi: https://doi.org/10.1016/j.ijscr.2017.08.041
Sato K, Tazawa H, Fujisaki S, Fukuhara S, Imaoka K, Hirata Y, Takahashi M, Fukuda S, Kuga Y, Nishida T, Sakimoto H. Acute diffuse peritonitis due to spontaneous rupture of a primary gastrointestinal stromal tumor of the jejunum: A case report. Int J Surg Case Rep. 2017;39:288-292. doi: 10.1016/j.ijscr.2017.08.041. Epub 2017 Aug 23. PMID: 28888914; PMCID: PMC5596258.
Copy Download .nbib Format: NLM
Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.

Oncotarget

Omae K, Tsujimoto Y, Honda M, Kondo T, Tanabe K, Fukuhara S, Furukawa TA.
PMID: 28978165
Oncotarget. 2017 Aug 18;8(40):68890-68898. doi: 10.18632/oncotarget.20323. eCollection 2017 Sep 15.

OBJECTIVE: To determine the comparative efficacy and safety of all available bone-modifying agents (BMAs) for the treatment of bone metastases in patients with advanced renal cell carcinoma (RCC).RESULTS: Three studies (259 patients) were identified for the systematic review. Two...

Cite
Omae K, Tsujimoto Y, Honda M, et al. Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8(40):68890-68898doi: 10.18632/oncotarget.20323.
Omae, K., Tsujimoto, Y., Honda, M., Kondo, T., Tanabe, K., Fukuhara, S., & Furukawa, T. A. (2017). Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Oncotarget, 8(40), 68890-68898. https://doi.org/10.18632/oncotarget.20323
Omae, Kenji, et al. "Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis." Oncotarget vol. 8,40 (2017): 68890-68898. doi: https://doi.org/10.18632/oncotarget.20323
Omae K, Tsujimoto Y, Honda M, Kondo T, Tanabe K, Fukuhara S, Furukawa TA. Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017 Aug 18;8(40):68890-68898. doi: 10.18632/oncotarget.20323. eCollection 2017 Sep 15. PMID: 28978165; PMCID: PMC5620305.
Copy Download .nbib Format: NLM
A patient with Alzheimer's disease complicated by elderly-onset Cushing's syndrome who had undergone surgical treatment for adrenocorticotropic hormone-independent macronodular adrenal hyperplasia.

Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society

Haraguchi Y, Mizoguchi Y, Noguchi T, Arai T, Fukuyama J, Kato TA, Kawashima T, Monji A.
PMID: 26370184
Psychogeriatrics. 2016 Jul;16(4):274-276. doi: 10.1111/psyg.12146. Epub 2015 Sep 15.

Cushing's syndrome (CS) is a rare disorder, especially in older people. Loss of brain volume and neurocognitive impairment of varying degrees has been demonstrated in patients with CS. However, there is a large difference between the median age of...

Cite
Haraguchi Y, Mizoguchi Y, Noguchi T, et al. A patient with Alzheimer's disease complicated by elderly-onset Cushing's syndrome who had undergone surgical treatment for adrenocorticotropic hormone-independent macronodular adrenal hyperplasia. Psychogeriatrics. 2015;16(4):274-276doi: 10.1111/psyg.12146.
Haraguchi, Y., Mizoguchi, Y., Noguchi, T., Arai, T., Fukuyama, J., Kato, T. A., Kawashima, T., & Monji, A. (2016). A patient with Alzheimer's disease complicated by elderly-onset Cushing's syndrome who had undergone surgical treatment for adrenocorticotropic hormone-independent macronodular adrenal hyperplasia. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 16(4), 274-276. https://doi.org/10.1111/psyg.12146
Haraguchi, Yoshinori, et al. "A patient with Alzheimer's disease complicated by elderly-onset Cushing's syndrome who had undergone surgical treatment for adrenocorticotropic hormone-independent macronodular adrenal hyperplasia." Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society vol. 16,4 (2016): 274-276. doi: https://doi.org/10.1111/psyg.12146
Haraguchi Y, Mizoguchi Y, Noguchi T, Arai T, Fukuyama J, Kato TA, Kawashima T, Monji A. A patient with Alzheimer's disease complicated by elderly-onset Cushing's syndrome who had undergone surgical treatment for adrenocorticotropic hormone-independent macronodular adrenal hyperplasia. Psychogeriatrics. 2016 Jul;16(4):274-276. doi: 10.1111/psyg.12146. Epub 2015 Sep 15. PMID: 26370184.
Copy Download .nbib Format: NLM
Erratum to: Impact of energy loss index on left ventricular mass regression after aortic valve replacement.

Journal of echocardiography

Koyama T, Okura H, Kume T, Fukuhara K, Imai K, Hayashida A, Neishi Y, Kawamoto T, Tanemoto K, Yoshida K.
PMID: 27279048
J Echocardiogr. 2014 Jun;12(2):59. doi: 10.1007/s12574-014-0208-2.

No abstract available.

Cite
Koyama T, Okura H, Kume T, et al. Erratum to: Impact of energy loss index on left ventricular mass regression after aortic valve replacement. J Echocardiogr. 2014;12(2):59doi: 10.1007/s12574-014-0208-2.
Koyama, T., Okura, H., Kume, T., Fukuhara, K., Imai, K., Hayashida, A., Neishi, Y., Kawamoto, T., Tanemoto, K., & Yoshida, K. (2014). Erratum to: Impact of energy loss index on left ventricular mass regression after aortic valve replacement. Journal of echocardiography, 12(2), 59. https://doi.org/10.1007/s12574-014-0208-2
Koyama, Terumasa, et al. "Erratum to: Impact of energy loss index on left ventricular mass regression after aortic valve replacement." Journal of echocardiography vol. 12,2 (2014): 59. doi: https://doi.org/10.1007/s12574-014-0208-2
Koyama T, Okura H, Kume T, Fukuhara K, Imai K, Hayashida A, Neishi Y, Kawamoto T, Tanemoto K, Yoshida K. Erratum to: Impact of energy loss index on left ventricular mass regression after aortic valve replacement. J Echocardiogr. 2014 Jun;12(2):59. doi: 10.1007/s12574-014-0208-2. PMID: 27279048; PMCID: PMC4969815.
Copy Download .nbib Format: NLM
Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K.
PMID: 25088236
Hepatol Res. 2015 Jun;45(6):656-62. doi: 10.1111/hepr.12400. Epub 2014 Sep 02.

AIM: To assess the efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis (PVT) in patients with liver cirrhosis.METHODS: A consecutive 26 cirrhotic patients with PVT were enrolled in this retrospective cohort...

Cite
Naeshiro N, Aikata H, Hyogo H, et al. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2014;45(6):656-62doi: 10.1111/hepr.12400.
Naeshiro, N., Aikata, H., Hyogo, H., Kan, H., Fujino, H., Kobayashi, T., Fukuhara, T., Honda, Y., Nakahara, T., Ohno, A., Miyaki, D., Murakami, E., Kawaoka, T., Tsuge, M., Hiraga, N., Hiramatsu, A., Imamura, M., Kawakami, Y., Ochi, H., & Chayama, K. (2015). Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology, 45(6), 656-62. https://doi.org/10.1111/hepr.12400
Naeshiro, Noriaki, et al. "Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 45,6 (2015): 656-62. doi: https://doi.org/10.1111/hepr.12400
Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2015 Jun;45(6):656-62. doi: 10.1111/hepr.12400. Epub 2014 Sep 02. PMID: 25088236.
Copy Download .nbib Format: NLM
Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer.

Molecular and clinical oncology

Kume H, Kawai T, Nagata M, Azuma T, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Fukuhara H, Homma Y.
PMID: 25798258
Mol Clin Oncol. 2015 Mar;3(2):303-307. doi: 10.3892/mco.2014.469. Epub 2014 Dec 01.

This study was conducted with the aim to investigate the feasibility of intermittent treatment with docetaxel chemotherapy for castration-resistant prostate cancer (CRPC). A total of 51 men with CRPC received docetaxel at 75 mg/m

Cite
Kume H, Kawai T, Nagata M, et al. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol. 2014;3(2):303-307doi: 10.3892/mco.2014.469.
Kume, H., Kawai, T., Nagata, M., Azuma, T., Miyazaki, H., Suzuki, M., Fujimura, T., Nakagawa, T., Fukuhara, H., & Homma, Y. (2015). Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Molecular and clinical oncology, 3(2), 303-307. https://doi.org/10.3892/mco.2014.469
Kume, Haruki, et al. "Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer." Molecular and clinical oncology vol. 3,2 (2015): 303-307. doi: https://doi.org/10.3892/mco.2014.469
Kume H, Kawai T, Nagata M, Azuma T, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Fukuhara H, Homma Y. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol. 2015 Mar;3(2):303-307. doi: 10.3892/mco.2014.469. Epub 2014 Dec 01. PMID: 25798258; PMCID: PMC4360872.
Copy Download .nbib Format: NLM
Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

United European gastroenterology journal

Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T.
PMID: 27403304
United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13.

BACKGROUND AND AIM: This prospective randomized study was designed to assess the efficacy of 10-day and 14-day rifabutin-based triple therapy as a third- or fourth-line rescue therapy.METHODS: Patients who failed first- and second-line eradication therapy were enrolled. H. pylori...

Cite
Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J. 2015;4(3):380-7doi: 10.1177/2050640615618043.
Mori, H., Suzuki, H., Matsuzaki, J., Tsugawa, H., Fukuhara, S., Miyoshi, S., Hirata, K., Seino, T., Matsushita, M., Nishizawa, T., Masaoka, T., & Kanai, T. (2016). Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European gastroenterology journal, 4(3), 380-7. https://doi.org/10.1177/2050640615618043
Mori, Hideki, et al. "Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study." United European gastroenterology journal vol. 4,3 (2016): 380-7. doi: https://doi.org/10.1177/2050640615618043
Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13. PMID: 27403304; PMCID: PMC4924440.
Copy Download .nbib Format: NLM
Communication Impairment in Ultrasonic Vocal Repertoire during the Suckling Period of .

Frontiers in neuroscience

Lopatina OL, Furuhara K, Ishihara K, Salmina AB, Higashida H.
PMID: 28566999
Front Neurosci. 2017 May 17;11:266. doi: 10.3389/fnins.2017.00266. eCollection 2017.

Communication consists of social interaction, recognition, and information transmission. Communication ability is the most affected component in children with autism spectrum disorder (ASD). Recently, we reported that the

Cite
Lopatina OL, Furuhara K, Ishihara K, et al. Communication Impairment in Ultrasonic Vocal Repertoire during the Suckling Period of . Front Neurosci. 2017;11:266doi: 10.3389/fnins.2017.00266.
Lopatina, O. L., Furuhara, K., Ishihara, K., Salmina, A. B., & Higashida, H. (2017). Communication Impairment in Ultrasonic Vocal Repertoire during the Suckling Period of . Frontiers in neuroscience, 11266. https://doi.org/10.3389/fnins.2017.00266
Lopatina, Olga L, et al. "Communication Impairment in Ultrasonic Vocal Repertoire during the Suckling Period of ." Frontiers in neuroscience vol. 11 (2017): 266. doi: https://doi.org/10.3389/fnins.2017.00266
Lopatina OL, Furuhara K, Ishihara K, Salmina AB, Higashida H. Communication Impairment in Ultrasonic Vocal Repertoire during the Suckling Period of . Front Neurosci. 2017 May 17;11:266. doi: 10.3389/fnins.2017.00266. eCollection 2017. PMID: 28566999; PMCID: PMC5434149.
Copy Download .nbib Format: NLM
Experimental gastric endoscopic submucosal dissection: training in a porcine model.

Annals of gastroenterology

Kasapidis P, Bassioukas S, Mavrogenis G, Tribonias G, Delis K, Georgopoulos S, Christodoulou D, Emmanouil T, Paraskeva K, Panteris V, Papalois A, Triantafillidis J, Tsiamoulos Z, Fukuhara T, Komeda Y, Kashida H.
PMID: 28655983
Ann Gastroenterol. 2017;30(4):446-449. doi: 10.20524/aog.2017.0147. Epub 2017 Apr 12.

BACKGROUND: Endoscopic submucosal dissection (ESD) requires special skills and a long procedure time for a quality-controlled procedure. A universal training system remains to be established. Hands-on courses in animal models before advancing to the human colon appear to be...

Cite
Kasapidis P, Bassioukas S, Mavrogenis G, et al. Experimental gastric endoscopic submucosal dissection: training in a porcine model. Ann Gastroenterol. 2017;30(4):446-449doi: 10.20524/aog.2017.0147.
Kasapidis, P., Bassioukas, S., Mavrogenis, G., Tribonias, G., Delis, K., Georgopoulos, S., Christodoulou, D., Emmanouil, T., Paraskeva, K., Panteris, V., Papalois, A., Triantafillidis, J., Tsiamoulos, Z., Fukuhara, T., Komeda, Y., & Kashida, H. (2017). Experimental gastric endoscopic submucosal dissection: training in a porcine model. Annals of gastroenterology, 30(4), 446-449. https://doi.org/10.20524/aog.2017.0147
Kasapidis, Panagiotis, et al. "Experimental gastric endoscopic submucosal dissection: training in a porcine model." Annals of gastroenterology vol. 30,4 (2017): 446-449. doi: https://doi.org/10.20524/aog.2017.0147
Kasapidis P, Bassioukas S, Mavrogenis G, Tribonias G, Delis K, Georgopoulos S, Christodoulou D, Emmanouil T, Paraskeva K, Panteris V, Papalois A, Triantafillidis J, Tsiamoulos Z, Fukuhara T, Komeda Y, Kashida H. Experimental gastric endoscopic submucosal dissection: training in a porcine model. Ann Gastroenterol. 2017;30(4):446-449. doi: 10.20524/aog.2017.0147. Epub 2017 Apr 12. PMID: 28655983; PMCID: PMC5479999.
Copy Download .nbib Format: NLM
Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan.

United European gastroenterology journal

Suzuki H, Matsuzaki J, Okada S, Hirata K, Fukuhara S, Hibi T.
PMID: 24917957
United European Gastroenterol J. 2013 Jun;1(3):175-83. doi: 10.1177/2050640613485238.

BACKGROUND: The GerdQ scoring system may be a useful tool for managing gastro-oesophageal reflux disease. However, GerdQ has not been fully validated in Asian countries.OBJECTIVE: To validate the Japanese version of GerdQ and to compare this version to the...

Cite
Suzuki H, Matsuzaki J, Okada S, et al. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European Gastroenterol J. 2013;1(3):175-83doi: 10.1177/2050640613485238.
Suzuki, H., Matsuzaki, J., Okada, S., Hirata, K., Fukuhara, S., & Hibi, T. (2013). Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European gastroenterology journal, 1(3), 175-83. https://doi.org/10.1177/2050640613485238
Suzuki, Hidekazu, et al. "Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan." United European gastroenterology journal vol. 1,3 (2013): 175-83. doi: https://doi.org/10.1177/2050640613485238
Suzuki H, Matsuzaki J, Okada S, Hirata K, Fukuhara S, Hibi T. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European Gastroenterol J. 2013 Jun;1(3):175-83. doi: 10.1177/2050640613485238. PMID: 24917957; PMCID: PMC4040759.
Copy Download .nbib Format: NLM
Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells.

Biochemistry and biophysics reports

Saito K, Fujiwara T, Ota U, Hatta S, Ichikawa S, Kobayashi M, Okitsu Y, Fukuhara N, Onishi Y, Ishizuka M, Tanaka T, Harigae H.
PMID: 28955775
Biochem Biophys Rep. 2017 Jul 13;11:105-111. doi: 10.1016/j.bbrep.2017.07.006. eCollection 2017 Sep.

5-Aminolevulinic acid (ALA) is a precursor for the biosynthesis of porphyrins and heme. Although the oral administration of ALA has been widely applied in clinical settings, the dynamics of its absorption, metabolism, and excretion within enterocytes remain unknown. In...

Cite
Saito K, Fujiwara T, Ota U, et al. Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells. Biochem Biophys Rep. 2017;11:105-111doi: 10.1016/j.bbrep.2017.07.006.
Saito, K., Fujiwara, T., Ota, U., Hatta, S., Ichikawa, S., Kobayashi, M., Okitsu, Y., Fukuhara, N., Onishi, Y., Ishizuka, M., Tanaka, T., & Harigae, H. (2017). Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells. Biochemistry and biophysics reports, 11105-111. https://doi.org/10.1016/j.bbrep.2017.07.006
Saito, Kei, et al. "Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells." Biochemistry and biophysics reports vol. 11 (2017): 105-111. doi: https://doi.org/10.1016/j.bbrep.2017.07.006
Saito K, Fujiwara T, Ota U, Hatta S, Ichikawa S, Kobayashi M, Okitsu Y, Fukuhara N, Onishi Y, Ishizuka M, Tanaka T, Harigae H. Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells. Biochem Biophys Rep. 2017 Jul 13;11:105-111. doi: 10.1016/j.bbrep.2017.07.006. eCollection 2017 Sep. PMID: 28955775; PMCID: PMC5614713.
Copy Download .nbib Format: NLM
Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report.

Urology case reports

Fukuhara H, Kakizaki H, Kaneko H, Yamanobe T, Ushijima M, Kuboki Y, Tsuchiya N.
PMID: 28932689
Urol Case Rep. 2017 Sep 08;15:11-13. doi: 10.1016/j.eucr.2017.08.001. eCollection 2017 Nov.

Urothelial carcinoma of the bladder (UCB) with glandular differentiation is a histological variant (HV) that is more likely to have positive extravesical tumors or nodes than those in pure UCB. Cisplatin-based neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC)...

Cite
Fukuhara H, Kakizaki H, Kaneko H, et al. Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report. Urol Case Rep. 2017;15:11-13doi: 10.1016/j.eucr.2017.08.001.
Fukuhara, H., Kakizaki, H., Kaneko, H., Yamanobe, T., Ushijima, M., Kuboki, Y., & Tsuchiya, N. (2017). Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report. Urology case reports, 1511-13. https://doi.org/10.1016/j.eucr.2017.08.001
Fukuhara, Hiroki, et al. "Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report." Urology case reports vol. 15 (2017): 11-13. doi: https://doi.org/10.1016/j.eucr.2017.08.001
Fukuhara H, Kakizaki H, Kaneko H, Yamanobe T, Ushijima M, Kuboki Y, Tsuchiya N. Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report. Urol Case Rep. 2017 Sep 08;15:11-13. doi: 10.1016/j.eucr.2017.08.001. eCollection 2017 Nov. PMID: 28932689; PMCID: PMC5595231.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 692 entries